TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens

摘要: Abstract Objective In cell line studies, BCL-2 and BAX proteins interfere with cancer response to taxanes. This issue has not received much attention regard taxane-platinum (TP)-treated ovarian patients. Methods We evaluated prognostic/predictive significance of TP53 status. Immunohistochemical analysis was performed on 199 carcinomas FIGO stage IIB–IV treated TP; the results were analyzed by Cox logistic regression models. Results Clinicopathological parameters (residual tumor size, and/or grade, but patient's age) only or strongest predictors outcome. Platinum highly sensitive showed a positive association accumulation ( p =0.045). As in our previously published platinum-cyclophosphamide-treated group, complete remission borderline negative (paradoxic) high expression whole group =0.058) TP53(−) =0.058). Conclusion Our suggest that TP53, carry some predictive potential taxane-platinum-treated patients, auxiliary clinicopathological factors. have confirmed another patient clinical importance may depend